PH12017500809B1 - Improved il-6 antibodies - Google Patents

Improved il-6 antibodies

Info

Publication number
PH12017500809B1
PH12017500809B1 PH1/2017/500809A PH12017500809A PH12017500809B1 PH 12017500809 B1 PH12017500809 B1 PH 12017500809B1 PH 12017500809 A PH12017500809 A PH 12017500809A PH 12017500809 B1 PH12017500809 B1 PH 12017500809B1
Authority
PH
Philippines
Prior art keywords
antibodies
improved
treatment
disclosed
diseases
Prior art date
Application number
PH1/2017/500809A
Other languages
English (en)
Other versions
PH12017500809A1 (en
Inventor
Eric Steven Furfine
Michael March Schmidt
Alison Tisdale
Gregory Zarbis-Papastoitsis
Original Assignee
F Hoffmann La Roche Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche Ltd filed Critical F Hoffmann La Roche Ltd
Publication of PH12017500809A1 publication Critical patent/PH12017500809A1/en
Publication of PH12017500809B1 publication Critical patent/PH12017500809B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH1/2017/500809A 2014-11-07 2015-11-06 Improved il-6 antibodies PH12017500809B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462077105P 2014-11-07 2014-11-07
US201462087448P 2014-12-04 2014-12-04
US201562247705P 2015-10-28 2015-10-28
PCT/US2015/059532 WO2016073890A1 (en) 2014-11-07 2015-11-06 Improved il-6 antibodies

Publications (2)

Publication Number Publication Date
PH12017500809A1 PH12017500809A1 (en) 2017-10-02
PH12017500809B1 true PH12017500809B1 (en) 2023-09-20

Family

ID=54602042

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2017/500809A PH12017500809B1 (en) 2014-11-07 2015-11-06 Improved il-6 antibodies

Country Status (32)

Country Link
US (3) US11142571B2 (OSRAM)
EP (3) EP3215530B9 (OSRAM)
JP (1) JP6594438B2 (OSRAM)
KR (2) KR102770849B1 (OSRAM)
CN (1) CN107249631B (OSRAM)
AU (1) AU2015342882B2 (OSRAM)
CA (1) CA2965689C (OSRAM)
CL (1) CL2017001135A1 (OSRAM)
CO (1) CO2017005404A2 (OSRAM)
CR (1) CR20170231A (OSRAM)
DK (2) DK4268843T3 (OSRAM)
EA (1) EA035199B1 (OSRAM)
ES (1) ES2756275T3 (OSRAM)
FI (1) FI4268843T3 (OSRAM)
HR (2) HRP20251312T1 (OSRAM)
HU (1) HUE046181T2 (OSRAM)
IL (1) IL251858B (OSRAM)
LT (1) LT4268843T (OSRAM)
MA (1) MA51554A (OSRAM)
MX (2) MX385206B (OSRAM)
MY (1) MY185114A (OSRAM)
PE (1) PE20171107A1 (OSRAM)
PH (1) PH12017500809B1 (OSRAM)
PL (2) PL3215530T3 (OSRAM)
PT (2) PT3215530T (OSRAM)
RS (2) RS59805B1 (OSRAM)
SA (1) SA517381458B1 (OSRAM)
SG (2) SG11201703574VA (OSRAM)
SI (1) SI3215530T1 (OSRAM)
UA (1) UA122673C2 (OSRAM)
WO (1) WO2016073890A1 (OSRAM)
ZA (1) ZA201702985B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201911226QA (en) 2015-09-23 2020-01-30 Genentech Inc Optimized variants of anti-vegf antibodies
WO2017147293A1 (en) * 2016-02-23 2017-08-31 Eleven Biotherapeutics, Inc. Il-6 antagonist formulations and uses thereof
EA201991207A1 (ru) * 2016-12-19 2019-12-30 Гленмарк Фармасьютикалс С.А. Новые агонисты tnfr и их применение
CN110891611B (zh) 2017-03-22 2024-03-29 阿森迪斯制药公司 水凝胶交联透明质酸前药组合物和方法
JP7227151B2 (ja) 2017-03-22 2023-02-21 ジェネンテック， インコーポレイテッド 眼障害の治療のために最適化された抗体組成物
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
EP4126949A1 (en) 2020-03-24 2023-02-08 Genentech, Inc. Tie2-binding agents and methods of use
JP2023546112A (ja) 2020-10-15 2023-11-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 長時間作用型眼送達用非共有結合タンパク質－ヒアルロナンコンジュゲート
CN114525235B (zh) * 2022-02-25 2023-07-14 郑州大学 一种提高人表皮生长因子分泌生产效率的方法
CN115343483B (zh) * 2022-08-12 2024-11-26 苏州邦器生物技术有限公司 一种自身免疫性糖尿病检测用试剂盒及其制备方法
CA3264497A1 (en) * 2022-10-24 2024-05-02 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
TW311927B (OSRAM) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
JP2005532313A (ja) 2002-05-07 2005-10-27 コントロール・デリバリー・システムズ・インコーポレイテッド 薬物送達装置の形成方法
CA2506230A1 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
JP4503617B2 (ja) 2003-12-23 2010-07-14 ライナット ニューロサイエンス コーポレイション アゴニスト抗ｔｒｋＣ抗体および該抗体を用いる方法
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
PL1966244T3 (pl) 2005-12-30 2012-08-31 Merck Patent Gmbh Przeciwciała anty-il-6 zapobiegające wiązaniu il-6 skompleksowanego z il-6ralpha do gp130
CA2644405A1 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
MX2008014692A (es) 2006-05-19 2009-08-18 Alder Biopharmaceuticals Inc Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno.
CN105001332B (zh) * 2007-05-21 2018-12-04 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
CN101855336B (zh) 2007-09-14 2019-07-30 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
WO2009070243A2 (en) 2007-11-21 2009-06-04 Amgen Inc. Wise binding agents and epitopes
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
WO2009090189A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
PT2328616E (pt) 2008-08-05 2015-08-26 Novartis Ag Composições e métodos para anticorpos dirigidos à proteína c5 do complemento
JP5033921B2 (ja) 2008-09-12 2012-09-26 株式会社ケーディエフ 噴水装置
US20120005773A1 (en) 2008-10-01 2012-01-05 Aasen Eric D Transgenic plants with enhanced agronomic traits
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
MX2011005540A (es) 2008-11-26 2011-06-21 Glaxo Group Ltd Polipeptidos dominios variables de anticuerpos, y antagonistas.
CA2749200A1 (en) 2009-01-29 2010-08-05 Michael Bowen Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
PE20130643A1 (es) 2010-07-12 2013-06-07 Covx Technologies Ireland Ltd Conjugados de anticuerpos multifuncionales
UA120029C2 (uk) 2012-07-13 2019-09-25 Рош Глікарт Аг Спосіб зниження в'язкості біспецифічного антитіла до vegf/ang-2 та застосування такого антитіла для лікування судинних очних захворювань
KR20150070384A (ko) 2012-10-25 2015-06-24 메디뮨 엘엘씨 안정한 저점도 항체 제제
CN104903349B (zh) * 2012-11-08 2018-10-19 十一生物治疗股份有限公司 Il-6拮抗剂及其应用
SG10201912985RA (en) 2013-07-12 2020-02-27 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Also Published As

Publication number Publication date
RS67353B1 (sr) 2025-11-28
CL2017001135A1 (es) 2017-12-15
AU2015342882B2 (en) 2021-05-20
PT4268843T (pt) 2025-10-31
MY185114A (en) 2021-04-30
PT3215530T (pt) 2019-11-21
US20250059270A1 (en) 2025-02-20
SI3215530T1 (sl) 2020-02-28
CO2017005404A2 (es) 2017-10-31
WO2016073890A1 (en) 2016-05-12
HUE046181T2 (hu) 2020-02-28
MX385206B (es) 2025-03-14
CA2965689C (en) 2022-03-22
US11142571B2 (en) 2021-10-12
DK4268843T3 (da) 2025-11-10
PE20171107A1 (es) 2017-08-07
JP2017535285A (ja) 2017-11-30
EP3215530B9 (en) 2020-09-09
CN107249631A (zh) 2017-10-13
DK3215530T3 (da) 2019-11-25
SG11201703574VA (en) 2017-05-30
PL3215530T3 (pl) 2020-05-18
MA51554A (fr) 2020-11-18
EP4268843A2 (en) 2023-11-01
KR102770849B1 (ko) 2025-02-20
HRP20251312T1 (hr) 2025-12-05
EA035199B1 (ru) 2020-05-14
CN107249631B (zh) 2021-11-23
FI4268843T3 (fi) 2025-11-14
PH12017500809A1 (en) 2017-10-02
HK1244008A1 (en) 2018-07-27
US20220169719A1 (en) 2022-06-02
SA517381458B1 (ar) 2020-07-09
KR20170077196A (ko) 2017-07-05
MX2021008663A (es) 2021-08-19
US20190194312A1 (en) 2019-06-27
RS59805B1 (sr) 2020-02-28
EP4268843A3 (en) 2023-12-27
BR112017008672A2 (pt) 2018-03-20
EA201791005A1 (ru) 2017-09-29
AU2015342882A1 (en) 2017-05-18
JP6594438B2 (ja) 2019-10-23
SG10202103420PA (en) 2021-05-28
MX2017005992A (es) 2017-09-15
EP3215530A1 (en) 2017-09-13
EP3215530B1 (en) 2019-08-21
LT4268843T (lt) 2025-11-25
ZA201702985B (en) 2019-10-30
UA122673C2 (uk) 2020-12-28
EP4268843B1 (en) 2025-09-03
ES2756275T9 (es) 2020-10-29
KR20240023450A (ko) 2024-02-21
IL251858A0 (en) 2017-06-29
CA2965689A1 (en) 2016-05-12
EP3632931A1 (en) 2020-04-08
NZ731090A (en) 2024-03-22
PL4268843T3 (pl) 2025-12-15
KR102636726B1 (ko) 2024-02-13
CR20170231A (es) 2017-09-25
IL251858B (en) 2022-09-01
ES2756275T3 (es) 2020-04-27
HRP20191945T1 (hr) 2020-01-24

Similar Documents

Publication Publication Date Title
MY185114A (en) Improved il-6 antibodies
JOP20200192A1 (ar) أجسام مضادة لـ tigit
PH12016501763B1 (en) Multispecific antibodies
MX2015005831A (es) Antagonistas de il-6 y usos de los mismos.
MY192927A (en) Fused bicyclic compounds for the treatment of disease
PH12018500578A1 (en) Methods of treating inflammatory diseases
EP3122782A4 (en) Compositions and methods for treatment of diabetic macular edema
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2016012758A (es) Composicion hiperosmolar de acido hialuronico.
EP3183270A4 (en) Hiv antibody therapy as treatment substitute
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
AR120118A2 (es) Anticuerpos anti tigit
HK1235307A1 (en) Methods for treating ocular diseases
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes